Exact Sciences CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Brian Baranick, EVP of Exact Sciences, reported the disposition of all his common stock and derivative holdings following the company's acquisition by Abbott Laboratories.
Exact Sciences' SVP, General Counsel & Secretary, James Herriott, reported the disposition of all his Exact Sciences common stock, options, and restricted stock units following the company's merger with Abbott Laboratories.
Exact Sciences' EVP and CFO, Aaron Bloomer, reported the disposition of common stock and restricted stock units following the company's merger with Abbott Laboratories.
Exact Sciences' EVP of Human Resources, Sarah Condella, reported the disposition of all her common stock, options, and restricted stock units following the company's acquisition by Abbott Laboratories.
Exact Sciences CEO Kevin T. Conroy reported significant changes in his beneficial ownership of company securities following the merger with Abbott Laboratories, converting equity and options into cash.
Jacob Orville, EVP at Exact Sciences, reported the disposition of common stock, stock options, and restricted stock units following the company's merger with Abbott Laboratories' subsidiary.
Exact Sciences Director D. Scott Coward reported the disposition of all common stock and stock options following the company's merger with Abbott Laboratories.
Exact Sciences Director Shacey Petrovic disposed of all common stock holdings following the company's acquisition by Abbott Laboratories for $105.00 per share.
Exact Sciences Director Katherine S. Zanotti reported the disposal of all her common stock holdings following the company's acquisition by Abbott Laboratories for $105.00 per share in cash.
Kimberly J. Popovits, a director at Exact Sciences Corp., disposed of all her common stock holdings following the company's merger with a subsidiary of Abbott Laboratories.
Exact Sciences Director James Edward Doyle disposed of all his common stock holdings following the company's merger with Abbott Laboratories.
Exact Sciences Director Paul J. Clancy disposed of all his common stock holdings following the company's merger into a wholly-owned subsidiary of Abbott Laboratories for $105.00 per share.
Exact Sciences Director Michael J. Barber reported the disposition of all common stock and deferred stock units following the company's merger with Abbott Laboratories.
Leslie Trigg, a director of Exact Sciences Corp., reported the disposition of all her common stock holdings following the company's merger with Abbott Laboratories' subsidiary.
Exact Sciences CEO Kevin T. Conroy reported the vesting of restricted stock units and subsequent tax-related share dispositions, increasing his direct beneficial ownership.
Exact Sciences' EVP of Human Resources, Sarah Condella, was granted 23,224 restricted stock units, vesting over four years.
Exact Sciences' SVP, General Counsel & Secretary, James Herriott, received a grant of 20,321 restricted stock units, increasing his beneficial ownership.
Exact Sciences CEO Kevin T. Conroy reported the vesting of restricted stock units, related tax withholding, and a new RSU grant.
EVP Brian Baranick of Exact Sciences Corp. reported the acquisition of 28,063 restricted stock units, increasing his total beneficial ownership.
Exact Sciences EVP Jacob A. Orville was granted 38,707 restricted stock units, vesting over four years.
Exact Sciences' Chief Financial Officer, Aaron Bloomer, was granted 28,063 restricted stock units, vesting over four years.
Exact Sciences EVP Jacob Orville accelerated the vesting of over 145,000 restricted stock units and performance shares in anticipation of the pending merger with Abbott Laboratories.
Exact Sciences' EVP Brian Baranick accelerated the vesting of over 100,000 shares of common stock and restricted units due to a pending merger with Abbott Laboratories.
Exact Sciences' EVP of Human Resources, Sarah Condella, reported significant equity transactions, including accelerated vesting of restricted stock units, in anticipation of the pending merger with Abbott Laboratories.
Exact Sciences CEO Kevin Conroy accelerated the vesting of performance-based restricted share units, totaling 713,931 shares, in connection with a pending merger with Abbott Laboratories to mitigate tax impacts.
Exact Sciences' SVP, General Counsel & Secretary, James Herriott, accelerated the vesting of over 100,000 restricted stock units and performance shares on December 23, 2025, in anticipation of the pending merger with Abbott Laboratories.
Exact Sciences CFO Aaron Bloomer reported the vesting of restricted stock units and subsequent tax-related share disposals, with some vesting accelerated due to Section 280G Mitigation.
Exact Sciences EVP, Jacob A. Orville, sold 5,000 shares of common stock for $75 per share, totaling $375,000, under a pre-arranged 10b5-1 plan.
Exact Sciences' SVP and General Counsel, James Herriott, sold 1,000 shares of common stock for $70 per share under a pre-arranged 10b5-1 trading plan.
Exact Sciences SVP James Herriott sold 1,500 shares of common stock for $70.08 per share under a pre-arranged 10b5-1 trading plan.